Today: 1 March 2026
Subscribe
Browse Category

NASDAQ:GLTO 7 October 2025 - 10 November 2025

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto said it acquired Damora Therapeutics and raised $284.9 million in an oversubscribed private placement, extending its cash runway into 2029. The moves shift Galecto’s focus to mutant calreticulin therapies for myeloproliferative neoplasms. GLTO shares surged about 285% in pre-market trading. No shareholder vote was required for the acquisition.
10 November 2025
··
Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

Galecto Inc. (NASDAQ: GLTO) shares soared over 600% in pre-market trading on Oct. 7, 2025, with more than 42 million shares traded despite no new company news. The stock, previously a low-float penny biotech, briefly touched $10 before retreating. Galecto has no revenue, heavy losses, and ended Q2 with $10.2 million in cash. Analysts remain cautious, citing high financial risk and limited coverage.
7 October 2025
·
Go toTop